0208080893 [email protected]
Providers / Bioss Primary Conjugated Antibodies. ALEXA FLUOR / EBV Nuclear Antigen Antibody, ALEXA FLUOR 594

Description:

Size: 100ul

Catalog no.: bs-6938R-A594

Price: 380 EUR

Get for 380 EUR on Gentaur.com

/ningbo-assets-bio/graphics/prods/bigs/bigs12.jpg

Product details

Virus

ebv

Modification Site

None

Crossreactivity

Virus

Subcellular location

Nucleus

French translation

anticorps

Tested applications

IF(IHC-P)

Modification

Unmodified

Clonality

Polyclonal

Immunogen range

550-600/641

Excitation emission

590nm/617nm

Concentration

1ug per 1ul

Conjugated with

ALEXA FLUOR® 594

Conjugated

Alexa conjugate 1

Cross-reactive species details

Epstein Barr Virus

Recommended dilutions

IF(IHC-P)(1:50-200)

Target Antigen

EBV Nuclear Antigen

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Category

Conjugated Primary Antibodies

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Host Organism

Rabbit (Oryctolagus cuniculus)

Also known as

Anti-EBV Nuclear Antigen PAb ALEXA FLUOR 594

Specificity

This is a highly specific antibody against EBV Nuclear Antigen.

Source

KLH conjugated synthetic peptide derived from EBV Nuclear Antigen

Long name

EBV Nuclear Antigen Polyclonal Antibody, ALEXA FLUOR 594 Conjugated

Description

Antigens are peptides or recombinant or native dependent on the production method.

Synonyms

EBNA1; EBNA-1; EBV nuclear antigen 1; Epstein Barr nuclear antigen 1; Epstein Barr virus; BKRF1; Epstein-Barr nuclear antigen 1; EBV nuclear antigen 1;

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.